This list includes look-alike and sound-alike name pairs. Use this list to determine which medications require special safeguards to reduce the risk of errors and minimize harm.
Resource Library
Whether you have experienced a medication error in your organization or you are proactively implementing prevention strategies, you are not alone. Thousands of organizations worldwide have relied on ISMP's resources for institutional change to reduce errors on a daily basis. These resources are developed from ISMP's review of reports through its national error reporting programs, peer-reviewed articles in its publications, and/or consensus gathering summits on topics pertinent to specific errors or hazards. ISMP offers a wide range of downloadable and easy to use resources. Many are free.
All Resources
Use this list to determine which medications require special safeguards to reduce the risk of errors and minimize harm.
Beyond Blame is a must-see for all who are responsible for patient care. The award-winning DVD introduces viewers to “Just Culture,” a way of thinking that fixes problems rather than assigning fault.
Although vaccination ranks high among the greatest public health achievements of the twentieth century, the success of any individual vaccine relies on correct and widespread administration to the appropriate patient population. Vaccine errors threaten to undermine the protection immunizations...
Hospira, a Pfizer company, released a letter last week, in coordination with the US Food and Drug Administration (FDA), detailing instructions for handling certain drugs and lot numbers of CARPUJECT glass syringes that may have cracked needle hubs and/or contain particulate matter. The list includes...
Problem: Earlier this month, ISMP held its second national summit on smart infusion pumps. The first summit, held in 2008, examined smart pump implementation, drug libraries, and clinical practice, and resulted in publication of the ISMP Guidelines for Safe Implementation and Use of Smart Infusion...
The latest issue of ISMP’s QuarterWatch™ (see description at the end of the article) examines drug safety issues identified by monitoring new adverse drug event reports submitted to the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). New data received during the third...
Limited regulatory guidance exists for investigational drug labeling, packaging, and nomenclature, exposing sites that participate in clinical trials to many troubling product-related safety risks. Many of these risks are unique to investigational drugs and are less likely to be encountered with US...
An investigational drug is a chemical or biological substance that has been tested in the laboratory and approved by the US Food and Drug Administration (FDA) for testing in people during clinical trials. Investigational drugs can include both prescription and nonprescription medications, but some...